Navigation Links
CytImmune Presents Positive CYT-6019 Data During the American,Society of Clinical Oncology Annual Meeting in Chicago

oiding uptake by the liver and spleen and (2) target delivery of TNF directly to tumor sites.

At 27 nanometers in size, these nanoparticles are small enough to circulate safely through the body but too large to exit the blood stream except through the newly formed and leaky vasculature at solid tumors. TNF molecules on the surface of these gold nanoparticles act as tumor-targeting agents, binding to receptors at the site of disease and pulling nearly all TNF out of the circulation. By selectively accumulating TNF in and around solid tumors, Aurimune limits the biodistribution of TNF and prevents its uptake by healthy organs and tissues.

Preliminary data from the Phase 1 study indicates that CYT-6091 is seen in tumors, but not in healthy tissue, and that the mechanism of targeting solid tumors is independent of tumor type. To date the drug has had no effect on renal, liver or immune function and no unexpected serious adverse events have been reported. CYT-6091 induces a predictable and controllable febrile response, and has yet to induce hypotension, the dose limiting toxic effect of TNF.

"The next step is to safely and systemically administer doses of TNF at levels similar to the clinical experience with isolated limb perfusion where efficacy (i.e. tumor regression) has been observed in 85% of patients treated," said Tamarkin. "If successful, such an achievement represents a significant step forward in advancing cancer therapy."

In preclinical studies, CytImmune achieved safe and targeted delivery of TNF at levels necessary for biologic response - in some cases far exceeding established lethal doses for TNF alone.

The Phase 1 clinical trial for CYT-6091 (Aurimune) began in May 2006 at the NCI Center for Cancer Research, Bethesda, MD. To date, 15 patients have participated in the study. Patients included in the study thus far have been late-stage pancreatic, breast, colon, melanoma, sarcoma and lung cancer sufferers. Twelve addition
'"/>




Page: 1 2 3

Related medicine technology :

1. CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to be Presented on June 3, 2007
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
(Date:5/5/2015)... Bio-Techne Corporation (NASDAQ: TECH ) announced ... a dividend of $0.32 per share for the quarter ... payable May 29, 2015 to all common shareholders of ... be considered by the Board of Directors on a ... ) is a global life sciences company providing innovative ...
(Date:5/5/2015)... 5, 2015  InMed Pharmaceuticals Inc. ("InMed") (CSE: ... that specializes in developing safer, more effective cannabis-based ... investor, and Non-Executive Director, Peter Mountford , ... with primary responsibility for the European markets. ... leverage his previous success in the emerging field ...
(Date:5/4/2015)... May 4, 2015  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, ... financial results for the first quarter ended March 31, ... "Following our equity offering in February, ... we are in a strong financial position to ...
Breaking Medicine Technology:InMed Engages Peter Mountford as Strategic Advisor 2InMed Engages Peter Mountford as Strategic Advisor 3InMed Engages Peter Mountford as Strategic Advisor 4Xencor Reports First Quarter 2015 Financial and Operating Results 2Xencor Reports First Quarter 2015 Financial and Operating Results 3Xencor Reports First Quarter 2015 Financial and Operating Results 4Xencor Reports First Quarter 2015 Financial and Operating Results 5Xencor Reports First Quarter 2015 Financial and Operating Results 6Xencor Reports First Quarter 2015 Financial and Operating Results 7Xencor Reports First Quarter 2015 Financial and Operating Results 8
... the journal Blood found 92 percent reduction in ... ... Patients with a rare,blood disorder called PNH experienced a 92 ... treatment,with Soliris(TM) (eculizumab), according to an analysis of clinical studies,recently ...
... Groundbreaking 2002 ... ... study reveals that,coiling, a minimally invasive procedure to treat aneurysms in ... treatment in those aneurysms considered "untouchable" by the,traditional surgical option. One ...
Cached Medicine Technology:PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 2New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 3
(Date:5/5/2015)... Grand Bahama (PRWEB) May 05, 2015 ... its Orthopedic Lifestyle Report today. The study was conducted ... conditions such as osteoarthritis and sports-related injuries ... pain and stiffness was the most prevalent symptom reported ... functionality such as walking, standing and bending over. Over ...
(Date:5/5/2015)... On May, 5, 2015, My Positive Perspective host Jason Deierlein ... for youngsters to do this summer. As the episode began, ... starting a summer camp and how is it going to ... Upon a Party and I come to children’s birthday parties ... We play games, sing, and dance and have a great ...
(Date:5/5/2015)... On April 8th, 2015, at the famous Avalon ... Durkin Entertainment’s “RockNRolla” EcoLuxe Lounge, a daylong event organized ... placement in TV and film. , A gathering ... sound and socially conscious products and services, the EcoLuxe ... appearances at various awards ceremonies and festivals each year, ...
(Date:5/5/2015)... For the growing list of high temperature monitoring demands, ... data logger series is based on a compact, ... throughout exposure to high temperatures and submersion without compromise. ... storing up to 32,700 readings and feature a user replaceable ... longer. All data loggers in the HiTemp140 series can be ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Don’t have ... money for a fitness membership? Don’t know which workout ... these obstacles in order to help members achieve their ... Live Streaming Fitness, an educational, caused-based wellness company, today ... live streaming fitness classes led by certified trainers, nutritional ...
Breaking Medicine News(10 mins):Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 2Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 3Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 4Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 5Health News:MadgeTech High Temperature Data Logger Series Expands for Growing Demands 6Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 2Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 3
... 11 Hope Solution, a 501-C3 nonprofit organization, is ... webcast telethon at Sojourner-Douglass College , located in ... 16th from 12noon to 6pm, and will raise money ... treatment options and dietary supplements.To view the Multimedia News ...
... offices and deserted restaurants are,a real possibility if the ... The public has been suffering from "gloom,fatigue" with constant ... threat,of this flu outbreak has been ignored. But this ... the year with dire results. Two of the EIU,s,top ...
... Africa,s healthcare markets are ... economic slowdown. Pressures from the global environment have ... resources.(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO )"Countries that have been ... driven by commodity exports," says Frost & Sullivan ...
... Nearly all off-the-shelf liquid hand sanitizers and hand wipes are alcohol ... prevent. Alcohol dries the skin causing cracks that open a direct ... non-toxic and non-alcohol hand sanitizers. , ... Erath, Louisiana ...
... A new analysis finds that a considerable number of ... financial connections to pharmaceutical companies. Published in the June ... journal of the American Cancer Society, the study indicates ... report biased results that are favorable to companies. , ...
... in blood vessels from triggering a later-stage, frequently lethal ... in the journal Nature Medicine . By eliminating ... (CypA) from a strain of mice, researchers were able ... , The aorta is the main artery carrying ...
Cached Medicine News:Health News:Not All Gloomy for African Healthcare Markets: Frost & Sullivan Finds Potential Despite the Recession 2Health News:Not All Gloomy for African Healthcare Markets: Frost & Sullivan Finds Potential Despite the Recession 3Health News:Q-Based Healthcare Warns: Hand Sanitizers Increase Risk of Swine Flu Exposure 2Health News:Q-Based Healthcare Warns: Hand Sanitizers Increase Risk of Swine Flu Exposure 3Health News:Review finds conflicts of interest in many cancer studies 2Health News:Study in Nature Medicine establishes major new treatment target in diseased arteries 2Health News:Study in Nature Medicine establishes major new treatment target in diseased arteries 3Health News:Study in Nature Medicine establishes major new treatment target in diseased arteries 4
Codman periosteal elevators, sharp, length 8" (203 mm), blade width 3/16" (5 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Adson periosteal elevators, No. 4 straight, semi-sharp edge, blade width 5/16" (8 mm), length 6 1/2" (165 mm)....
West 2 periosteal elevators....
Medicine Products: